Know Cancer

forgot password

A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma

Phase 1/Phase 2
18 Years
80 Years
Open (Enrolling)
Hepatocellular Carcinoma

Thank you

Trial Information

A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma

This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in
2 phases: a dose-escalation phase, to determine the MTD of CF102 and to evaluate its
safety/tolerability, PK, pharmacodynamic, and preliminary clinical activity; and a
dose-confirmation phase, which will be a cohort expansion at or below the MTD (ie, the RP2D)
of CF102. Subjects will be treated with oral doses of CF102 in consecutive, 28-day cycles.
The initial dose of CF102 will be 1 mg twice daily (BID), with subsequent escalations to 5
and 25 mg BID, unless limited by toxicity. Subjects will be evaluated weekly for the first
cycle, every 2 weeks for Cycles 2 and 3, and at the end of each subsequent cycle, up to 6
cycles of CF102 treatment. Subjects will return for a follow-up visit 28 days after
completion of the last dose of study drug.

Inclusion Criteria:

1. Diagnosis of HCC:

- For patients without underlying cirrhosis, diagnosis of HCC documented by
cytology and/or histology

- For patients with underlying cirrhosis, diagnosis of HCC established according
to the American Association for the Study of Liver Diseases Practice Guideline
algorithm (Appendix V).

2. HCC is advanced, refractory, or metastatic, and no standard therapies are expected to
be curative.

3. At least 18 years of age.

4. For subjects in the dose-confirmation (RP2D) phase only: Measurable disease, using
Response Evaluation Criteria in Solid Tumors (RECIST, Appendix IV). (Note that a
lesion that has been subjected to radiotherapy or chemoembolization cannot be used as
a target lesion.)

5. Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at

6. The following laboratory values must be documented within 3 days prior to initiation
of study drug:

- Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L

- Platelet count greater than or equal to 50 x 109/L

- Serum creatinine less than or equal to 2.0 mg/dL

- Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper
limit of normal.

- Total bilirubin ≤ 3.0 mg/dL.

- Serum albumin ≥ 3.0 g/dL.

- International normalized ratio (INR) ≤ 2.3.

7. Esophageal bleeding and varices, if present, have been sclerosed or banded, and no
bleeding episodes have occurred during the prior 6 months.

8. Life expectancy of ≥ 12 weeks.

9. For women of childbearing potential, negative serum pregnancy test result.

10. Absence of active malignancy other than HCC within 2 years of entry, with the
exception of basal cell carcinoma and squamous cell carcinoma of the skin.

11. Provide written informed consent to participate.

12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and
other study related procedures.


Exclusion Criteria:

1. Any chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy,
corticosteroids > 20 mg/day prednisone or equivalent, or growth factor treatment
(e.g., erythropoietin) within 14 days prior to initiation of study drug.

2. Major surgery or radiation therapy within 28 days prior to initiation of study drug.

3. Severe liver dysfunction (Child-Pugh Class C or hepatic encephalopathy).

4. Active infection requiring systemic therapy.

5. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or
4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral
artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within
3 months prior to initiation of study drug.

6. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation
of any grade, or persistent prolongation of the QTc (Fridericia) interval to > 450
msec for males or > 470 msec for females.

7. Pregnant or lactating female.

8. Women of childbearing potential, unless they agree to use dual contraceptive methods
which, in the opinion of the Principal Investigator (PI), are effective and adequate
for that patient's circumstances while on study drug.

9. Men who partner with a woman of childbearing potential, unless they agree to use
effective, dual contraceptive methods (i.e., a condom, with female partner using
oral, injectable, or barrier method) while on study drug.

10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related

11. Any severe, acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, may interfere with the informed consent process and/or with
compliance with the requirements of the study, or may interfere with the
interpretation of study results and, in the investigator's opinion, would make the
patient inappropriate for entry into this study.


Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Dose limiting toxicity and maximum tolerated dose

Outcome Time Frame:


Safety Issue:


Principal Investigator

Michael H Silverman, MD

Investigator Role:

Study Director

Investigator Affiliation:

Can-Fite BioPharma Ltd


United States: Food and Drug Administration

Study ID:




Start Date:

February 2009

Completion Date:

December 2012

Related Keywords:

  • Hepatocellular Carcinoma
  • Hepatocellular carcinoma
  • Hepatoma
  • HCC
  • Carcinoma
  • Carcinoma, Hepatocellular